{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplantation&page=51",
    "query": {
      "intervention": "Allogeneic hematopoietic stem cell transplantation",
      "page": 51
    },
    "page_size": 10
  },
  "pagination": {
    "page": 51,
    "page_size": 10,
    "total_count": 2012,
    "total_pages": 202,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplantation&page=52&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Allogeneic+hematopoietic+stem+cell+transplantation&page=50&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T13:42:19.079Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00295971",
      "title": "Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Congenital Amegakaryocytic Thrombocytopenia",
        "Leukemia",
        "Myelodysplastic Syndromes",
        "Severe Congenital Neutropenia"
      ],
      "interventions": [
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic allogeneic lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "thiotepa",
          "type": "DRUG"
        },
        {
          "name": "allogeneic bone marrow transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "in vitro-treated peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "1 Year to 17 Years"
      },
      "enrollment_count": 21,
      "start_date": "2005-04",
      "completion_date": "2011-12",
      "has_results": false,
      "last_update_posted_date": "2012-11-12",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 2,
      "location_summary": "San Francisco, California • Chapel Hill, North Carolina",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00295971"
    },
    {
      "nct_id": "NCT00721214",
      "title": "5-Azacytidine Prior to Allogeneic Stem Cell Transplant in High Risk Myelodysplastic Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndrome"
      ],
      "interventions": [
        {
          "name": "5-azacytidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virginia Commonwealth University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2008-07",
      "completion_date": "2014-06",
      "has_results": true,
      "last_update_posted_date": "2016-03-02",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00721214"
    },
    {
      "nct_id": "NCT06072612",
      "title": "Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Breast Cancer",
        "Breast Neoplasm",
        "Breast Cancer Metastatic",
        "End Stage Cancer"
      ],
      "interventions": [
        {
          "name": "SV-BR-1-GM",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Interferon infiltration of the inoculation site",
          "type": "DRUG"
        },
        {
          "name": "Retifanlimab",
          "type": "DRUG"
        },
        {
          "name": "Treatment of Physician's Choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "BriaCell Therapeutics Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 404,
      "start_date": "2023-12-05",
      "completion_date": "2028-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-02",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 79,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06072612"
    },
    {
      "nct_id": "NCT00301730",
      "title": "Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "aldesleukin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "therapeutic tumor infiltrating lymphocytes",
          "type": "BIOLOGICAL"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel",
          "type": "DRUG"
        },
        {
          "name": "conventional surgery",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1,
      "start_date": "2005-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2015-04-28",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00301730"
    },
    {
      "nct_id": "NCT03114865",
      "title": "A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Acute Lymphoblastic Leukemia",
        "B-cell Non Hodgkin Lymphoma",
        "Pre B-Cell Acute Lymphoblastic Leukaemia"
      ],
      "interventions": [
        {
          "name": "Blinatumomab 9ug",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab 28 ug",
          "type": "DRUG"
        },
        {
          "name": "Blinatumomab",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2017-09-05",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-22",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03114865"
    },
    {
      "nct_id": "NCT00847171",
      "title": "Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "allogeneic GM-CSF-secreting breast cancer vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "trastuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "flow cytometry",
          "type": "OTHER"
        },
        {
          "name": "immunoenzyme technique",
          "type": "OTHER"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 20,
      "start_date": "2008-12",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2018-09-26",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00847171"
    },
    {
      "nct_id": "NCT01161628",
      "title": "Rituximab for the Primary Treatment of Denovo Extensive Chronic Graft Versus Host Disease (GVHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Graft-versus-host Disease"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northside Hospital, Inc.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 25,
      "start_date": "2011-04",
      "completion_date": "2015-07",
      "has_results": true,
      "last_update_posted_date": "2016-04-20",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01161628"
    },
    {
      "nct_id": "NCT00861965",
      "title": "Bioengineered Allogeneic Immune Cells (AlloStim) Not Requiring HLA Donor Match for Blood Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced or Refractory Leukemia, Lymphoma, Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "AlloStim-8",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Mirror Biologics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2010-01",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2020-01-22",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 1,
      "location_summary": "Carlsbad, California",
      "locations": [
        {
          "city": "Carlsbad",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00861965"
    },
    {
      "nct_id": "NCT04554914",
      "title": "A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Epstein-Barr Virus (EBV)-Associated Diseases",
        "EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)",
        "EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)",
        "EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)",
        "EBV+ Post-transplant Lymphoproliferative Disease (EBV+ PTLD)",
        "Solid Organ Transplant Complications",
        "Lymphoproliferative Disorders",
        "Allogeneic Hematopoietic Cell Transplant",
        "Stem Cell Transplant Complications",
        "EBV+ Sarcomas",
        "Leiomyosarcoma"
      ],
      "interventions": [
        {
          "name": "Tabelecleucel",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Pierre Fabre Medicament",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 190,
      "start_date": "2021-07-14",
      "completion_date": "2028-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 23,
      "location_summary": "Los Angeles, California • Orange, California • Palo Alto, California + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04554914"
    },
    {
      "nct_id": "NCT03827967",
      "title": "Trial of PalloV-CC in Colon Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Cancer"
      ],
      "interventions": [
        {
          "name": "PalloV-CC",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "George E. Peoples",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2019-07-20",
      "completion_date": "2023-05-20",
      "has_results": false,
      "last_update_posted_date": "2023-09-13",
      "last_synced_at": "2026-10-24T13:42:19.079Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03827967"
    }
  ]
}